Analysts Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) Target Price at $14.00

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have received an average rating of “Reduce” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $14.00.

Several brokerages recently issued reports on IART. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and raised their price target for the stock from $11.00 to $16.00 in a report on Thursday, May 28th. Truist Financial cut their target price on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Wells Fargo & Company boosted their price target on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Argus reiterated a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Finally, Wall Street Zen upgraded Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors have recently bought and sold shares of IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after purchasing an additional 1,975 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Integra LifeSciences in the first quarter worth about $277,000. Goldman Sachs Group Inc. lifted its holdings in Integra LifeSciences by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after purchasing an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Integra LifeSciences by 23.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after purchasing an additional 45,693 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Integra LifeSciences in the second quarter worth about $491,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $17.77 on Wednesday. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -2.75, a price-to-earnings-growth ratio of 1.23 and a beta of 1.24. Integra LifeSciences has a 12-month low of $8.70 and a 12-month high of $18.05. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. The stock’s 50 day simple moving average is $13.28 and its 200 day simple moving average is $12.20.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.13. The business had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business’s revenue was up 2.4% on a year-over-year basis. During the same quarter last year, the business posted $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities research analysts expect that Integra LifeSciences will post 2.44 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.